Taysha Gene Therapies (NASDAQ:TSHA) Issues Quarterly Earnings Results

Taysha Gene Therapies (NASDAQ:TSHA) posted its quarterly earnings data on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01, Zacks reports. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA traded down $0.06 during mid-day trading on Wednesday, reaching $1.65. 355,961 shares of the stock were exchanged, compared to its average volume of 2,060,365. The company has a market capitalization of $337.13 million, a P/E ratio of 2.61 and a beta of 0.93. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The business’s 50 day moving average is $1.69 and its 200-day moving average is $1.99. Taysha Gene Therapies has a 1 year low of $1.19 and a 1 year high of $4.32.

Analyst Ratings Changes

TSHA has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a report on Monday, January 6th. Canaccord Genuity Group increased their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, November 15th. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, Chardan Capital reissued a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $6.63.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.